Study guide
10.7 Inspection Methods, Self-Audits & Continuous Readiness
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
10.7 Inspection Methods, Self-Audits & Continuous Readiness
Key Takeaways Explain This Topic AI
Sterile compounding programs face several kinds of inspection: internal self-audits, state board inspections (often with required self-inspection forms), FDA inspections (for cause at 503A pharmacies, routine and risk-based at 503B facilities), and accreditation surveys such as The Joint Commission's.
Inspectors combine document review, direct observation of garbing and aseptic technique, staff interviews, facility walk-throughs and tracers that follow a CSP from order to administration.
The Joint Commission's tracer method follows real patients and processes across departments to test whether practice matches policy, rather than reviewing documents alone.
Continuous readiness means current SOPs, complete and retrievable records, excursions investigated and closed, and staff who can explain their tasks, so any day could be inspection day.
After an inspection, findings go into CAPA with effectiveness checks. For FDA Form 483 observations, FDA considers responses received within 15 business days.
Last updated: September 2026
10.7 Inspection Methods, Self-Audits & Continuous Readiness
Sterile compounding is inspected more often than most pharmacy work, and the BCSCP outline expects you to know how those inspections are done (task 3A5). It also expects you to run a program that is ready at any time, which the outline calls continuous readiness under quality management (3A3).
Who inspects
Inspector Scope and typical trigger Notes
Internal auditors (designated person, quality staff, peers) Scheduled self-audits; after changes or excursions The most useful inspections, because you choose the depth
State board of pharmacy Routine licensure inspections, complaints, new or changed permits Many boards require annual self-inspection forms; Washington's, for example, has USP <797> and <800> addenda
FDA 503A: usually for cause (adverse events, complaints, state referral). 503B: risk-based surveillance inspections Findings are recorded on Form FDA 483 and may lead to a Warning Letter
CMS and state survey agencies Hospital Conditions of Participation, including pharmaceutical services and infection control Deficiencies can put Medicare participation at risk
Accreditors The Joint Commission (including its optional Medication Compounding Certification), ACHC/PCAB for compounding pharmacies Survey against their own standards, which build in USP <797> and <800>
NABP inspection programs Inspections that some state boards accept for nonresident (out-of-state) pharmacies Useful for pharmacies that ship across state lines
Inspection methods
Document review: SOPs and their review dates, training and competency files, certification reports, monitoring results and trends, cleaning logs, temperature and pressure logs, MFRs and CRs, investigations and CAPA, complaints and recalls.
Direct observation: watching hand hygiene, garbing order, glove disinfection, first-air discipline, cleaning technique and material transfer. Inspectors compare what they see with the SOP.
Interviews: asking a technician, "What do you do if the pressure alarm sounds?" or "Where is the spill kit, and when do you use a respirator?" Staff should answer from the SOP, not guess.
Environmental walk-through: leaks, damaged surfaces, cardboard, clutter, equipment placement, sink and drain locations, signs and access control for HD areas.
Tracers: following an actual CSP or patient through the system, from order, verification, compounding and labeling to storage, delivery, administration and monitoring. The Joint Commission's tracer method tests whether departments' processes connect and match their policies.
Data review: trends, repeat excursions and repeat competency failures that point to system weakness.
Running a self-audit or gap analysis
Build the checklist from the standard. State self-inspection forms, such as Washington's USP <797> addendum, which quotes the chapter section by section, are good starting templates. Add USP <800>, your state's rules and your accreditor's standards.
Score each requirement: compliant, not compliant, or not applicable, with evidence (the document, what was observed, who was interviewed).
Rank gaps by risk: patient harm first (sterility, dosing), then worker safety (HD containment), then documentation.
Assign a CAPA to each gap, with an owner, a due date and an effectiveness check.
Repeat at least annually, and after renovations, new equipment, new CSP categories or major excursions.
Mock tracers, where a colleague follows a CSP from start to finish, show handoff gaps that checklists miss.
Continuous readiness
Being ready every day means the following:
Records are complete and retrievable. USP <797> requires records to be readily retrievable. Monitoring results, certifications and training files should be found in minutes.
SOPs are current. Every SOP has been reviewed within 12 months, and practice matches the current version.
No open-ended excursions. Every out-of-range result has a documented investigation, corrective action and effectiveness check.
Competencies are on schedule. No compounder is working past a garbing or media-fill due date.
The environment is inspection-ready : no cardboard, no clutter, no damaged surfaces, and cleaning logs up to date.
Staff can explain their tasks, the reason for them, and what to do when something goes wrong.
During and after an inspection
Escort the inspectors, provide requested records promptly, answer factually, and never guess or volunteer speculation. Keep notes of what was asked and seen.
Fix simple findings on the spot where you can, and document that you did. An immediate fix does not remove the observation.
At the closing conference, make sure you understand each observation.
Respond in writing. For an FDA Form 483, FDA considers a response received within 15 business days before deciding on further action. State boards set their own deadlines.
Put every finding into CAPA , with root cause, corrective and preventive actions, and objective proof that they worked (see 12.1).
Preparing staff for inspector questions
Inspectors often ask front-line staff instead of managers. Common questions include:
- "Show me how you garb."
- "How often is the sporicidal applied, and where is that documented?"
- "What would you do if the pressure monitor alarmed during compounding?"
- "Where is the spill kit, and when do you wear a respirator?"
- "How do you know this BUD is right?"
Short practice rounds, where a peer asks the same questions, build confidence and expose gaps between the SOPs and actual practice. Keep a current document index so anyone can quickly find the SOP list, the last two certification reports, monitoring trends, competency status and open CAPAs.